Monthly olezarsen reduced triglycerides by 65% for people with severe hypertriglyceridemia, resulting in a greater than 85% ...
Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, ...
MedPage Today on MSN
Novel GLP-1 Drug on Attack Path Against Very High Triglycerides
During an AHA press conference, Li explained that each component of the triple-receptor agonist compensates for side effects ...
MedPage Today on MSN
Gene Therapy Shows Promise for Cutting LDL in Half in Tough-to-Treat Dyslipidemia
N EW ORLEANS – A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that ...
An investigational triple agonist that targets fibroblast growth factor 21, glucagon and GLP-1 receptors cut triglyceride ...
The single dose treatment helped patients lower “bad” cholesterol and triglyerides, both linked to heart disease ...
Clin Lipidology. 2009;4(4):425-437. Clinical event trials are urgently needed to assess treatment strategies for dyslipidemia management, including POM3 treatment, in patients with ...
A CRISPR-based gene therapy showed improvement in lipids in difficult-to-treat patients, but one study raised flags after a ...
Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). In ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback